



## **Final Appraisal Recommendation**

### **Tipranavir (Aptivus<sup>®</sup>▼) capsules**

**Limited submission by:  
Boehringer Ingelheim Ltd**

**Advice No: 2010 – December 2010**

### **Recommendation of AWMSG**

**Tipranavir (Aptivus<sup>®</sup>▼) capsules, co-administered with low dose ritonavir, are recommended as an option for use within NHS Wales, for combination antiretroviral treatment of HIV-1 infection in highly pre-treated adolescents 12 years of age or older with virus resistant to multiple protease inhibitors. Tipranavir (Aptivus<sup>®</sup>▼) should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options.**

**Tipranavir (Aptivus<sup>®</sup>▼) capsules are not suitable for shared care within NHS Wales for the above indication.**

#### **Additional notes:**

The potential for drug interactions should be taken into consideration when prescribing.

Differences in bioavailability should be noted when formulation changes are considered.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion, lay perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be used without the whole of the advice being quoted in full and should be cited as: